<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066233</url>
  </required_header>
  <id_info>
    <org_study_id>13-008214</org_study_id>
    <nct_id>NCT02066233</nct_id>
  </id_info>
  <brief_title>Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy</brief_title>
  <official_title>Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IntroMedic Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate whether a disposable nasal endoscope called &quot;E.G.
      Scan II&quot; will visualize the esophagus as well as the standard test, sedated endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects underwent two procedures: the E.G.Scan II followed by standard endoscopy in a
      tandem design. The E.G. Scan II is a transnasal endoscope system to capture and transmit
      images of the esophagus. Captured images can be reviewed via the E.G. View for diagnosis of
      diseases related to the esophagus. Generally, the commercial esophagoscope system has
      reusable probes, but E.G. Scanâ„¢ II has a single use probe because reusable probes have the
      risk of infection and pollution.

      Prior to the E.G.Scan, subjects received a standard prep for the procedure. The two
      procedures were performed by two different experienced endoscopists who were blinded to the
      indication of the procedure. At both procedures a note was made of any abnormality of the
      esophagus. Every subject with an endoscopic diagnosis of Barrett's Esophagus had clinical
      biopsies taken to confirm diagnosis. Subject tolerability was measured with a 10-point visual
      analog scale (VAS) where 0 represented the &quot;worst experience&quot; and 10 the &quot;best experience.&quot;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Tolerability Score on 10-point Visual Analog Scale (VAS)</measure>
    <time_frame>Within 48 hours</time_frame>
    <description>On the 10-point VAS, 0 represented the &quot;worst experience&quot; and 10 the &quot;best experience.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy</measure>
    <time_frame>Two weeks</time_frame>
    <description>Subjects were asked the following question: &quot;Based on the overall experience (including need for sedation, ability to drive, time off work, procedure comfort, procedure time, etc.). Which procedure would you prefer to have in the future?&quot; Possible answers were: Nasal camera test (EG), oral camera test (Gastroscopy), or either test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>Subjects with Barrett's Esophagus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with Reflux and/or Heartburn</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EG Scan II (transnasal endoscopy)</intervention_name>
    <arm_group_label>Subjects with Barrett's Esophagus</arm_group_label>
    <arm_group_label>Subjects with Reflux and/or Heartburn</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Endoscopy</intervention_name>
    <arm_group_label>Subjects with Barrett's Esophagus</arm_group_label>
    <arm_group_label>Subjects with Reflux and/or Heartburn</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult participants aged 18 years or above who are scheduled for routine upper GI
             endoscopy for Barrett's Esophagus surveillance, varices surveillance and dyspepsia.

          2. Able and willing to give informed consent.

        Exclusion Criteria:

          1. Patients known to be intolerant to endoscopy.

          2. Patients with frequent epistaxis.

          3. Patients not clinically fit for endoscopy as judged by their care team.

          4. Pregnant women.

          5. Patients with allergy/sensitivity to Simethicone (Mylicon), Phenylephrine, Lidocaine
             nasal spray, Benzocaine spray (Topex)

          6. Use of anticoagulants or antiplatelets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prasad G Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Prasad G. Iyer</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Barrett's</keyword>
  <keyword>esophagus</keyword>
  <keyword>reflux</keyword>
  <keyword>heartburn</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Barrett's Esophagus</title>
          <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
        </group>
        <group group_id="P2">
          <title>Subjects With Reflux and/or Heartburn</title>
          <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>EG Scan II (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>difficulty intubating subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Standard Endoscopy (Day 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Barrett's Esophagus</title>
          <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
        </group>
        <group group_id="B2">
          <title>Subjects With Reflux and/or Heartburn</title>
          <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.66" spread="11.62"/>
                    <measurement group_id="B2" value="51.72" spread="15.07"/>
                    <measurement group_id="B3" value="56.19" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Tolerability Score on 10-point Visual Analog Scale (VAS)</title>
        <description>On the 10-point VAS, 0 represented the &quot;worst experience&quot; and 10 the &quot;best experience.&quot;</description>
        <time_frame>Within 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Barrett's Esophagus</title>
            <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Subjects With Reflux and/or Heartburn</title>
            <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Tolerability Score on 10-point Visual Analog Scale (VAS)</title>
          <description>On the 10-point VAS, 0 represented the &quot;worst experience&quot; and 10 the &quot;best experience.&quot;</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EG II Scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standard Endoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy</title>
        <description>Subjects were asked the following question: &quot;Based on the overall experience (including need for sedation, ability to drive, time off work, procedure comfort, procedure time, etc.). Which procedure would you prefer to have in the future?&quot; Possible answers were: Nasal camera test (EG), oral camera test (Gastroscopy), or either test.</description>
        <time_frame>Two weeks</time_frame>
        <population>Two subjects on the reflux and/or heartburn arm didn't answer this question.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Barrett's Esophagus</title>
            <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
          </group>
          <group group_id="O2">
            <title>Subjects With Reflux and/or Heartburn</title>
            <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy</title>
          <description>Subjects were asked the following question: &quot;Based on the overall experience (including need for sedation, ability to drive, time off work, procedure comfort, procedure time, etc.). Which procedure would you prefer to have in the future?&quot; Possible answers were: Nasal camera test (EG), oral camera test (Gastroscopy), or either test.</description>
          <population>Two subjects on the reflux and/or heartburn arm didn't answer this question.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Camera Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Camera Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Either Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Presenting adverse events per per intervention was not possible, as most patients were sedated prior to the procedures and only a few were not sedated. Therefore the adverse events were per patient population (study arm).</desc>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Barrett's Esophagus</title>
          <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
        </group>
        <group group_id="E2">
          <title>Subjects With Reflux and/or Heartburn</title>
          <description>All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gagging/Retching</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="44"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="44"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="44"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="44"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nose Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Prasad G. Iyer</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-6469</phone>
      <email>Iyer.Prasad@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

